Oxazolidin-2-one prostaglandin compounds
    41.
    发明授权
    Oxazolidin-2-one prostaglandin compounds 失效
    恶唑烷-2-酮前列腺素化合物

    公开(公告)号:US4410526A

    公开(公告)日:1983-10-18

    申请号:US323152

    申请日:1981-11-20

    摘要: Compounds of the formula: ##STR1## and the pharmaceutically acceptable, non-toxic salts and esters (alkyl, 1-6C) thereof, wherein:X is O or S;R.sup.1 is selected from the group consisting of:(a) alkyl or cycloalkyl of 3-8 carbons, ##STR2## R.sup.2 is hydrogen or methyl; exhibit prostaglandin-like activity and are, thus, useful as platelet aggregation inhibitors.

    摘要翻译: 式(I)化合物及其药学上可接受的无毒盐和酯(烷基,1-6C),其中:X是O或S; R1选自:(a)3-8个碳原子的烷基或环烷基,(b) CH2,Y是低级烷基(1-4C),低级烷氧基(1-4C),卤素, 或CF3,和(c)本文定义的 并且R 2是氢或甲基; 表现出前列腺素样活性,因此可用作血小板聚集抑制剂。

    Bis(benzylpyrrolidine) derivatives useful for treating congestive heart
failure and acute renal failure
    49.
    发明授权
    Bis(benzylpyrrolidine) derivatives useful for treating congestive heart failure and acute renal failure 失效
    用于治疗充血性心力衰竭和急性肾衰竭的双(苄基吡咯烷)衍生物

    公开(公告)号:US5135944A

    公开(公告)日:1992-08-04

    申请号:US801244

    申请日:1991-12-03

    CPC分类号: C07D207/08 C07D207/333

    摘要: Compounds of Formula I ##STR1## in which: R.sub.1 is hydrogen, lower alkyl, --C(O)R.sub.3, or --C(O)NR.sub.3 R.sub.4, where R.sub.3 and R.sub.4 are independently lower alkyl, phenyl, or phenyl lower alkyl;R.sub.2 is hydrogen or lower alkyl; andX is --(CH.sub.2).sub.m -- where m is an integer of 1 to 10, or --(CH.sub.2).sub.n Y(CH.sub.2).sub.n -- where n is an integer of 1 to 3 and Y is oxygen or sulfur,their individual R,R-; R,S-; and S,S-stereoisomers, and racemic or non-racemic mixtures of stereoisomers, and their pharmaceutically acceptable salts are dopamine agonist compounds useful in the treatment of hypertension and congestive heart failure in mammals.

    摘要翻译: 式I的化合物其中:R 1是氢,低级烷基,-C(O)R 3或-C(O)NR 3 R 4,其中R 3和R 4独立地是低级烷基,苯基或苯基低级烷基 ; R2是氢或低级烷基; X为 - (CH 2)m - ,其中m为1〜10的整数,或 - (CH 2)n Y(CH 2)n - ,其中n为1〜3的整数,Y为氧或硫, R-; R,S-; 和S,S-立体异构体,以及立体异构体的外消旋或非外消旋混合物及其药学上可接受的盐是可用于治疗哺乳动物高血压和充血性心力衰竭的多巴胺激动剂化合物。